211 related articles for article (PubMed ID: 29463989)
1. Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development.
Sung YC; Liu YC; Chao PH; Chang CC; Jin PR; Lin TT; Lin JA; Cheng HT; Wang J; Lai CP; Chen LH; Wu AY; Ho TL; Chiang T; Gao DY; Duda DG; Chen Y
Theranostics; 2018; 8(4):894-905. PubMed ID: 29463989
[TBL] [Abstract][Full Text] [Related]
2. Dual-Functional Nanoparticles Targeting CXCR4 and Delivering Antiangiogenic siRNA Ameliorate Liver Fibrosis.
Liu CH; Chan KM; Chiang T; Liu JY; Chern GG; Hsu FF; Wu YH; Liu YC; Chen Y
Mol Pharm; 2016 Jul; 13(7):2253-62. PubMed ID: 27224003
[TBL] [Abstract][Full Text] [Related]
3. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.
Chen Y; Huang Y; Reiberger T; Duyverman AM; Huang P; Samuel R; Hiddingh L; Roberge S; Koppel C; Lauwers GY; Zhu AX; Jain RK; Duda DG
Hepatology; 2014 Apr; 59(4):1435-47. PubMed ID: 24242874
[TBL] [Abstract][Full Text] [Related]
5. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
Chen Y; Liu YC; Sung YC; Ramjiawan RR; Lin TT; Chang CC; Jeng KS; Chang CF; Liu CH; Gao DY; Hsu FF; Duyverman AM; Kitahara S; Huang P; Dima S; Popescu I; Flaherty KT; Zhu AX; Bardeesy N; Jain RK; Benes CH; Duda DG
Sci Rep; 2017 Mar; 7():44123. PubMed ID: 28276530
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel-carboxymethylcellulose nanoparticles ameliorate CCl
Chang CC; Yang Y; Gao DY; Cheng HT; Hoang B; Chao PH; Chen LH; Bteich J; Chiang T; Liu JY; Li SD; Chen Y
J Drug Target; 2018; 26(5-6):516-524. PubMed ID: 29251522
[TBL] [Abstract][Full Text] [Related]
7. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
8. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells.
Zhang Z; Yao Z; Wang L; Ding H; Shao J; Chen A; Zhang F; Zheng S
Autophagy; 2018; 14(12):2083-2103. PubMed ID: 30081711
[TBL] [Abstract][Full Text] [Related]
9. Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.
Liu JY; Chiang T; Liu CH; Chern GG; Lin TT; Gao DY; Chen Y
Mol Ther; 2015 Nov; 23(11):1772-1782. PubMed ID: 26278330
[TBL] [Abstract][Full Text] [Related]
10. CREKA-modified liposomes target activated hepatic stellate cells to alleviate liver fibrosis by inhibiting collagen synthesis and angiogenesis.
Li R; Zhang J; Liu Q; Tang Q; Jia Q; Xiong Y; He J; Li Y
Acta Biomater; 2023 Sep; 168():484-496. PubMed ID: 37392933
[TBL] [Abstract][Full Text] [Related]
11. Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis.
Hassan R; Tammam SN; Safy SE; Abdel-Halim M; Asimakopoulou A; Weiskirchen R; Mansour S
Eur J Pharm Biopharm; 2019 Jan; 134():96-106. PubMed ID: 30471341
[TBL] [Abstract][Full Text] [Related]
12. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
Wang W; Xu B; Li Q; Jiang D; Yan S
Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
[TBL] [Abstract][Full Text] [Related]
13. Collagenase Type I and Probucol-Loaded Nanoparticles Penetrate the Extracellular Matrix to Target Hepatic Stellate Cells for Hepatic Fibrosis Therapy.
Wang X; Zhang W; Zeng S; Wang L; Wang B
Acta Biomater; 2024 Feb; 175():262-278. PubMed ID: 38141933
[TBL] [Abstract][Full Text] [Related]
14. CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation.
Ullah A; Wang K; Wu P; Oupicky D; Sun M
Int J Nanomedicine; 2019; 14():2927-2944. PubMed ID: 31118614
[No Abstract] [Full Text] [Related]
15. Activated hepatic stellate cells regulate MDSC migration through the SDF-1/CXCR4 axis in an orthotopic mouse model of hepatocellular carcinoma.
Xu Y; Fang F; Jiao H; Zheng X; Huang L; Yi X; Zhao W
Cancer Immunol Immunother; 2019 Dec; 68(12):1959-1969. PubMed ID: 31641797
[TBL] [Abstract][Full Text] [Related]
16. Metformin attenuates motility, contraction, and fibrogenic response of hepatic stellate cells
Li Z; Ding Q; Ling LP; Wu Y; Meng DX; Li X; Zhang CQ
World J Gastroenterol; 2018 Feb; 24(7):819-832. PubMed ID: 29467552
[TBL] [Abstract][Full Text] [Related]
17. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis.
Wang Y; Gao J; Zhang D; Zhang J; Ma J; Jiang H
J Hepatol; 2010 Jul; 53(1):132-44. PubMed ID: 20447716
[TBL] [Abstract][Full Text] [Related]
18. Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
Lo Re O; Panebianco C; Porto S; Cervi C; Rappa F; Di Biase S; Caraglia M; Pazienza V; Vinciguerra M
J Cell Physiol; 2018 Feb; 233(2):1202-1212. PubMed ID: 28471474
[TBL] [Abstract][Full Text] [Related]
19. Matrix stiffness modulates hepatic stellate cell activation into tumor-promoting myofibroblasts via E2F3-dependent signaling and regulates malignant progression.
Liu Z; Mo H; Liu R; Niu Y; Chen T; Xu Q; Tu K; Yang N
Cell Death Dis; 2021 Dec; 12(12):1134. PubMed ID: 34873170
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
